184 related articles for article (PubMed ID: 20886687)
21. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e.
Li R; Lim A; Ow ST; Phoon MC; Locht C; Chow VT; Alonso S
Vaccine; 2011 Jul; 29(33):5502-11. PubMed ID: 21624415
[TBL] [Abstract][Full Text] [Related]
22. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis.
Reveneau N; Alonso S; Jacob-Dubuisson F; Mercenier A; Locht C
Vaccine; 2001 Dec; 20(5-6):926-33. PubMed ID: 11738759
[TBL] [Abstract][Full Text] [Related]
23. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models.
Li R; Cheng C; Chong SZ; Lim AR; Goh YF; Locht C; Kemeny DM; Angeli V; Wong WS; Alonso S
Allergy; 2012 Oct; 67(10):1250-8. PubMed ID: 22909095
[TBL] [Abstract][Full Text] [Related]
24. Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin.
Steinman L; Weiss A; Adelman N; Lim M; Oehlert J; Zuniga R; Hewlett E; Falkow S
Dev Biol Stand; 1985; 61():439-46. PubMed ID: 2872126
[TBL] [Abstract][Full Text] [Related]
25. [General immunogenesis after oral uptake of killed Pertussis bacteria].
Hof H; Finger H
Zentralbl Bakteriol Orig A; 1974; 227(1-4):282-8. PubMed ID: 4154597
[No Abstract] [Full Text] [Related]
26. Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
Medeiros MA; Armôa GR; Dellagostin OA; McIntosh D
Can J Microbiol; 2005 Dec; 51(12):1015-20. PubMed ID: 16462859
[TBL] [Abstract][Full Text] [Related]
27. Protection against intranasal infection of mice with Bordetella pertussis.
Robinson A; Ashworth LA; Baskerville A; Irons LI
Dev Biol Stand; 1985; 61():165-72. PubMed ID: 2872102
[TBL] [Abstract][Full Text] [Related]
28. Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Peppoloni S; Pizza M; De Magistris MT; Bartoloni A; Rappuoli R
Physiol Chem Phys Med NMR; 1995; 27(4):355-61. PubMed ID: 8768791
[TBL] [Abstract][Full Text] [Related]
29. Genetic studies of the molecular basis of whooping cough.
Weiss AA; Hewlett EL; Myers GA; Falkow S
Dev Biol Stand; 1985; 61():11-9. PubMed ID: 2872097
[TBL] [Abstract][Full Text] [Related]
30. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Kamachi K; Arakawa Y
Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047
[TBL] [Abstract][Full Text] [Related]
31. Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Rappuoli R; Pizza M; Covacci A; Bartoloni A; Nencioni L; Podda A; De Magistris MT
FEMS Microbiol Immunol; 1992 Oct; 5(4):161-70. PubMed ID: 1384602
[TBL] [Abstract][Full Text] [Related]
32. Towards third-generation whooping cough vaccines.
Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L
Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047
[TBL] [Abstract][Full Text] [Related]
33. Molecular aspects of Bordetella pertussis pathogenesis.
Locht C
Int Microbiol; 1999 Sep; 2(3):137-44. PubMed ID: 10943406
[TBL] [Abstract][Full Text] [Related]
34. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.
Nascimento IP; Dias WO; Quintilio W; Christ AP; Moraes JF; Vancetto MD; Ribeiro-Dos-Santos G; Raw I; Leite LC
Microbes Infect; 2008 Feb; 10(2):198-202. PubMed ID: 18248757
[TBL] [Abstract][Full Text] [Related]
35.
Teruya S; Hiramatsu Y; Nakamura K; Fukui-Miyazaki A; Tsukamoto K; Shinoda N; Motooka D; Nakamura S; Ishigaki K; Shinzawa N; Nishida T; Sugihara F; Maeda Y; Horiguchi Y
mBio; 2020 Mar; 11(2):. PubMed ID: 32209694
[TBL] [Abstract][Full Text] [Related]
36. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
[TBL] [Abstract][Full Text] [Related]
37. Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
Calver GA
Biologicals; 1999 Jun; 27(2):143-7. PubMed ID: 10600203
[TBL] [Abstract][Full Text] [Related]
38. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
Hausman SZ; Burns DL
Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544
[TBL] [Abstract][Full Text] [Related]
39. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
[TBL] [Abstract][Full Text] [Related]
40. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
Boucher P; Sato H; Sato Y; Locht C
Infect Immun; 1994 Feb; 62(2):449-56. PubMed ID: 7507893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
